NR3C1 and prostate carcinoma: Bicalutamide and darolutamide but not apalutamide treatment significantly upregulated NR3C1 and SLC7A11 expression (Supplementary Figure S4), demonstrating that AR antagonist-induced transcription in prostate cancer cells is not limited to a single AR antagonist.